2023 European Society of Cardiology guidelines for the management of acute coronary syndromes
Netherlands Heart Journal · 2024 · Europe
Source and licence
- Authors
- Bastiaan Zwart, Bimmer E P M Claessen, Peter Damman et al.
- Title
- 2023 European Society of Cardiology guidelines for the management of acute coronary syndromes
- Journal
- Netherlands Heart Journal, 2024
- Licence
- CC BY 4.0
- Changes
- Verbatim excerpts; formatting adapted
Full text retrieved 2026-10-27 from Europe PMC · PMC11413259
Licence statement of the original publication
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
This page reproduces excerpts of the original publication; the original is authoritative. It has not been reviewed by a physician, does not state a recommendation of Medelix and does not replace medical advice. The guideline may have been updated since.
This is a review of another guideline (2023 ESC Guidelines for the management of acute coronary syndromes, ESC 2023). We do not reproduce that guideline's recommendations here – they belong to the original guideline.
Open the original publication →Full text on Europe PMC
Abstract
This review discusses the new recommendations in the 2023 European Society of Cardiology guidelines on the management of acute coronary syndrome and provides a perspective on topics specific to clinical practice in the Netherlands, including pre-treatment, antiplatelet agent strategies, the use of risk scores and logistical considerations with regard to the timing of coronary angiography.
Contents of the original publication
The section headings of the original.
- Introduction
- Pre-treatment
- P2Y12 inhibitor pre-treatment in STEMI
- Anticoagulation pre-treatment in STEMI
- P2Y12 inhibitor pre-treatment in NSTE-ACS
- Choice of P2Y12 inhibitor in ACS
- Anticoagulation in NSTE-ACS
- Antithrombotic therapy and use of risk scores
- Antithrombotic therapy
- Triple therapy
- Risk scores
- Timing of invasive coronary angiography
- ST-elevation myocardial infarction
- Non-ST-elevation acute coronary syndrome
- Invasive coronary angiography in resuscitated patients after cardiac arrest
- Transfer to PCI centre
- Completeness and timing of revascularisation
A question about this guideline?
Medelix answers clinical questions from guidelines and studies – every statement with its source.
Are you the rights holder and object to this reproduction? Write to contact@medelix.ai and we will take the page down promptly. Imprint